Psyence Biomedical Faces Nasdaq Non-Compliance Challenge
Friday, 15 March 2024, 20:37
Psyence Biomedical Faces Nasdaq Non-Compliance Challenge
Psyence Biomedical recently received a non-compliance notification from Nasdaq due to certain deviations. The company's stock is under scrutiny, leading to concerns among investors about its performance. Psyence Biomedical now faces the challenge of addressing the issues highlighted by the Nasdaq to regain compliance and maintain its standing in the market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.